8-K current report · filed Nov 12, 2026

Monopar Therapeutics (MNPR) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1MNPR overview

Short answer

Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.

Monopar Therapeutics 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing the company’s reported results and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net loss widened to $6.2M, or $0.72 per share, from $3.4M, or $0.48 per share
  • Cash, equivalents and investments totaled $129.4M, supporting operations through at least March 31, 2028
  • NDA submission for ALXN1840 remains on track for completion within the next several weeks
  • Phase 3 findings showed residual disease burden despite treatment, supporting potential unmet need in Wilson disease
  • R&D expenses rose to $4.44M from $2.59M, reflecting higher contractors, consulting and personnel costs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Monopar Therapeutics 8-K filings

Get the next MNPR 8-K as it lands

Follow MNPR for push alerts, or ask the research agent what this filing means.